

Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy

Angela Rita Elia, Matteo Grioni, Veronica Basso, et al.

Clin Cancer Res 2018;24:2171-2181. Published OnlineFirst February 28, 2018.

Updated version	Access the most recent version of this article at: doi: 10.1158/1078-0432.CCR-17-2210
Supplementary Material	Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2018/02/28/1078-0432.CCR-17-2210.DC1

Cited articles	This article cites 46 articles, 19 of which you can access for free at: http://clincancerres.aacrjournals.org/content/24/9/2171.full#ref-list-1
Citing articles	This article has been cited by 1 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/24/9/2171.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/24/9/2171 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.